ONCOLOGY Vol 40, Issue 1

In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Structured exercise interventions may mitigate TRAE, such as fatigue, but data in metastatic RCC are limited.

New MCL research spotlights BTK inhibitors, CAR-T advances, MRD-guided trials, and TP53-driven risk, reshaping frontline and relapse care.

Discover how stem cell transplant still deepens myeloma remission, guided by MRD and paired with CAR‑T, bispecifics, and smarter maintenance.